Compare Cytokinetics Inc (CYTK) vs Dolby Laboratories, Inc. (DLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Dolby Laboratories, Inc. — how do they compare? Cytokinetics Inc trades at $62.1 (market cap $8.62B), while Dolby Laboratories, Inc. trades at $58.9 (market cap $5.47B). The key difference: Cytokinetics Inc is the larger of the two by market cap, and Dolby Laboratories, Inc. pays a 2.46% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Dolby Laboratories, Inc. for 98 Days on average.
| CYTK | DLB | |
|---|---|---|
Market Cap | $8.62B | $5.47B |
Volume | 2,594,626 | 1,058,284 |
Sector | Health | Technology |
52-Week High | $87.26 | $70.09 |
52-Week Low | $54.76 | $48.51 |
Typical Hold Time | 19 Days | 98 Days |
Enterprise Value | $8.72B | $4.85B |
Dividend Yield | — | 2.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
Dolby Laboratories (DLB) trades at $58.35, down 0.19% with bearish technical signals. The company maintains strong profitability with 87.61% gross margins and has beaten earnings estimates for three consecutive quarters. Recent developments include expanded partnerships with Meta and leadership transition to new CEO Marc Whitten. Cash flow improved significantly in 2025 with $472M operating cash flow.
DLB presents a mixed outlook with strong fundamentals but technical weakness. The 47% upside to $90.33 consensus target offers potential, though near-term execution risks and licensing volatility remain concerns. Revenue stability around $1.3B and premium valuation metrics require continued innovation execution to justify current multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →
